Randomized Controlled Multicenter Trial to Evaluate the Effects of Ethyl-2-cyanoacrylate on Pain Intensity and Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades During Radioimmunotherapy (SUPPORT)

NCT01693159 NA UNKNOWN

The SUPPORT trial is an open-label, prospective, randomized, national multicenter intervention study to evaluate the effectiveness of ethyl-2-cyanoacrylate versus the standard treatment of each institution on the pain intensity and QoL in patients with locally advanced head and neck cancer suffering from painful cetuximab-induced rhagades during radioimmunotherapy.

Details

Lead sponsor	National Center for Tumor Diseases, Heidelberg
Phase	NA
Status	UNKNOWN
Enrolment	50
Start date	2011-05
Completion	2018-11

Conditions

• Pain

Interventions

• ECA
• Standard topical treatment of the institution, e.g. Lotio

Primary outcomes

• pain intensity 24 hours after application of ECA or the standard treatment quantified by the visual analogue scale (VAS) — 24 hours after application
  pain intensity quantified by the visual analogue scale (VAS)

Countries

Germany